Drugs / NTX-001
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 23 trials | ||||||
| Phase 2 | NCT04789044 | Jun 2023 → Oct 2027 expected | peripheral nerve lesion | Major Extremity Trauma Research Consortium | Recruiting | No outcome recorded |
| Phase 2 | NCT05293522 | Jul 2022 → Aug 2023 | facial paralysis | Neuraptive Therapeutics Inc. | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT04572906 | Sep 2020 → Jun 2024 | peripheral nerve lesion | Neuraptive Therapeutics Inc. | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06616025 | Feb 2025 → Mar 2027 expected | peripheral nerve lesion | Neuraptive Therapeutics Inc. | Recruiting | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT05565846 | — | peripheral nerve lesion | Neuraptive Therapeutics Inc. | Available | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NTX-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06616025 ↗ |
| Known as | PEG-Fusion | “NTX-001 (PEG-Fusion)” NCT06616025 ↗ |
| Action | Restore | “By reconnecting (PEG-fusion) a substantial number of axons within a severed nerve” NCT06616025 ↗ |
| Route | Topical | “3 solutions applied topically” NCT04572906 ↗ |